As biologics and other advanced therapies become increasingly integral to modern healthcare, the demand for effective high-dose drug delivery continues to grow. These therapies often involve unique requirements, including larger dose volumes, concentrated formulations, and higher viscosities. Addressing these complexities is crucial, especially when the subcutaneous delivery route is preferred for its ability to enhance patient independence and reduce the burdens associated with intravenous administration.
At the same time, pharmaceutical companies face a variety of considerations when moving to subcutaneous high-dose delivery. Ensuring smooth delivery of viscous or high-volume drugs requires the right combination of device performance and patient-centric design. Precision dosing, seamless usability, and alignment with the specific properties of the formulation are all essential to successful implementation. These challenges also present opportunities for innovation, as the right delivery device can transform the patient experience while enhancing efficiency and value for pharmaceutical partners.
The Ypsomed approach to high-dose delivery
Ypsomed delivers state-of-the-art solutions for subcutaneous self-injection of high-dose drug formulations, underpinned by three core pillars:
1. High-dose capability for autoinjector platforms:
Our YpsoMate platform range is engineered to handle high volumes and viscosities with ease. With the recent introduction of an 8 mm thin-wall needle configuration — a first in the industry — it minimises injection times while prioritising patient comfort. With a proven track record of global success, YpsoMate combines engineering excellence and robust performance to meet diverse drug formulation needs.
2. Solutions for a wide range of therapies:
Ypsomed supports the transition from intravenous to subcutaneous delivery, enabling more therapies to be administered comfortably at home. We also expand selfcare opportunities by addressing the unique needs of emerging advanced therapies, ensuring our devices serve diverse patient populations. With 70 combination products spanning 15 therapy areas, our platforms make advanced therapies more accessible and transformative.
3. Simplicity and scalability for high-dose delivery:
Our handheld and patch injector solutions are platform products—designed for rapid customisation and seamless integration. These pre-tested, proven platforms reduce risks and shorten time-to-market, enabling pharmaceutical companies to bring therapies to patients faster. Prefilled and ready-to-use, they ensure ease of use and maintain compatibility with existing manufacturing and supply chain processes.
Supported by automated manufacturing and expert regulatory guidance, our innovative, high-dose solutions are transforming our partners’ ability to deliver therapies that enhance patient outcomes and reduce healthcare burdens.
Ypsomed’s high-dose delivery portfolio
YpsoMate 1.0
The YpsoMate 1.0 is designed for high-dose delivery in a compact volume of up to 1 mL, handling viscosities of up to 55 cP in just 6–10 seconds when configured with the 8 mm needle option. With its push-on-skin activation, this device offers simple, ergonomic handling that is intuitive and preferred by patients. Ideal for therapies requiring rapid delivery, YpsoMate 1.0 sets the standard for reliability and patient satisfaction.
YpsoMate 2.25 and YpsoMate 2.25 Pro
Designed for subcutaneous delivery of up to 2.25 mL, these platforms cater to a broad range of therapies. The YpsoMate 2.25 handles viscosities of up to 40 cP when configured with an 8 mm needle, completing injections in 10–15 seconds.
For higher viscosity formulations, the YpsoMate 2.25 Pro features a constant-force drive, enabling delivery of viscosities up to 50 cP with a half-inch needle and up to 80 cP with an 8 mm needle. Injection times for these configurations are approximately 15 seconds.
With their combination of reliability, precision, and patient comfort, and an extensive track record, these platforms meet the evolving demands of high-dose therapies.
YpsoMate 5.5
The YpsoMate 5.5 takes handheld autoinjectors to the next level, enabling delivery of volumes between 1.5 mL and 5.5 mL for viscosities up to 50 cP. Built on the trusted YpsoMate platform, it leverages advanced spring mechanisms to inject large volumes smoothly and consistently. Its configurable injection times, ranging from 10 to 60 seconds, make it a scalable solution for advanced biologics requiring higher doses.
YpsoDose
For the largest doses, YpsoDose is a groundbreaking patch injector capable of delivering up to 10 mL with viscosities of 50 cP. Its intuitive, prefilled design minimises handling steps and residual volume and ensures a seamless experience for patients and healthcare providers alike. With programmable injection times tailored to specific therapeutic needs, YpsoDose addresses the challenges of large-volume delivery while prioritising safety, reliability, and user comfort.
Viscosities and volumes for Ypsomed's subutaneous autoinjector devices
Volume and viscosity capabilities of Ypsomed’s advanced delivery devices. The YpsoMate 1.0 delivers up to 1 mL at 55 cP in a maximum of 10 seconds with its 8 mm needle configuration. The YpsoMate 2.25 supports up to 2.25 mL at 40 cP in 15 seconds using the 8 mm needle, while the YpsoMate 2.25 Pro handles 2.25 mL at 80 cP in 15 seconds with its 8 mm needle configuration. The YpsoMate 5.5 enables delivery of 5.5 mL at 50 cP within 45 seconds, and the YpsoDose patch injector delivers 10 mL at 50 cP in 10 minutes. These devices provide precise and reliable solutions for diverse subcutaneous delivery requirements.
Let’s partner for success
Are you looking to overcome the challenges of high-dose drug delivery with innovative, patient-focused solutions? Ypsomed’s portfolio of advanced autoinjectors and patch injectors offers the simplicity, scalability, and reliability you need to succeed in the competitive biopharmaceutical market.
Stay tuned, stay informed
Subscribe to the Ypsomed Blog and join our journey to simpler and easier selfcare.
